The Actavis Group is a leading player in the development, manufacture and sale of high-quality generic pharmaceuticals.
Actavis' recent acquisition of the generics business of Alpharma positions the company among the five leading generic pharmaceutical companies in the world, with 10,000 employees in over 30 countries. Founded in 1956, the Group now operates across five continents and has its headquarters in Iceland.
Today the Company has modern development and manufacturing facilities in Europe, the US and Asia. The plants produce a variety of medicines in different formulations including tablets, capsules, injectables, suppositories, sprays, steriles, powders, oral liquids and semi solids.
The Group has one of the broadest portfolios in the generics sector with over 600 products on the market, in addition to around 300 products in the development pipeline and in registration, enabling the Company to provide its customers with a wide range of affordable high quality pharmaceuticals.